Patents Assigned to MAPREG
  • NON-BIOCONVERTIBLE C3-SUBSTITUTED PREGNENOLONE DERIVATIVES FOR USE IN THE TREATMENT OF SUBSTANCE USE DISORDERS
    Publication number: 20210322443
    Abstract: The present invention relates to the use of non-bioconvertible C3-substituted pregnenolone derivatives of formula (I), with no significant affinity for hormonal receptors or receptors of the central nervous system, in the treatment of substance use disorders, and in particular of alcohol use disorder.
    Type: Application
    Filed: June 29, 2021
    Publication date: October 21, 2021
    Applicant: MAPREG
    Inventors: George F. KOOB, Barbara JEAN MASON, Olivier GEORGE, Etienne BAULIEU, Isabelle VILLEY
  • Non-bioconvertible C-substituted pregnenolone derivatives for use in the treatment of substance use disorders
    Patent number: 11077122
    Abstract: The present invention relates to the use of non-bioconvertible C3-substituted pregnenolone derivatives of formula (I), with no significant affinity for hormonal receptors or receptors of the central nervous system, in the treatment of substance use disorders, and in particular of alcohol use disorder.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: August 3, 2021
    Assignee: MAPREG
    Inventors: George F. Koob, Barbara Jean Mason, Olivier George, Etienne Baulieu, Isabelle Villey
  • Method for treating a degenerative disease of the nervous system using 3-methoxy-pregnenolone or derivatives thereof
    Patent number: 10561671
    Abstract: The present invention relates to a method of enhancing retention of recognition memory and/or recovering recognition memory deficits using 3?-methoxy-pregna-5-ene-20-one.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: February 18, 2020
    Assignee: MAPREG
    Inventors: Etienne-Emile Baulieu, Esther Fellous, Paul Robel
  • Non-bioconvertible C-substituted pregnenolone derivatives for use in the treatment of treatment-resistant depression
    Patent number: 9943528
    Abstract: The present invention relates to methods for the treatment of treatment-resistant depression (TRD), comprising the administration of compounds of formula (I), which are blocked in C3 position and cannot metabolize in vivo into pregnenolone derivatives and which do not have significant affinity for steroid hormonal receptors and for all tested classical main receptors and receptors of neurotransmitters of the central nervous system.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: April 17, 2018
    Assignee: MAPREG
    Inventors: Massimiliano Bianchi, Etienne Baulieu, Isabelle Villey
  • Non-Bioconvertible C3-Substituted Pregnenolone Derivatives for Use in the Treatment of Treatment-Resistant Depression
    Publication number: 20170252358
    Abstract: The present invention relates to methods for the treatment of treatment-resistant depression (TRD), comprising the administration of compounds of formula (I), which are blocked in C3 position and cannot metabolize in vivo into pregnenolone derivatives and which do not have significant affinity for steroid hormonal receptors and for all tested classical main receptors and receptors of neurotransmitters of the central nervous system.
    Type: Application
    Filed: February 28, 2017
    Publication date: September 7, 2017
    Applicant: MAPREG
    Inventors: Massimiliano BIANCHI, Etienne BAULIEU, Isabelle VILLEY
  • METHOD FOR TREATING A DEGENERATIVE DISEASE OF THE NERVOUS SYSTEM USING 3-METHOXY-PREGNENOLONE OR DERIVATIVES THEREOF
    Publication number: 20160166586
    Abstract: The present invention relates to a method for the treatment of a degenerative disease of the nervous system in a patient, comprising administering to said patient an effective quantity of 3?-methoxy-pregna-5-ene-20-one (3?-methoxy-PREG) or derivatives thereof.
    Type: Application
    Filed: November 24, 2015
    Publication date: June 16, 2016
    Applicant: MAPREG
    Inventors: Etienne-Emile BAULIEU, Esther FELLOUS, Paul ROBEL
  • Use of 3-methoxy-pregnenolone for the preparation of a drug for treating a traumatic brain injury
    Patent number: 9339508
    Abstract: A method for the treatment of a traumatic brain lesion comprises administering to the patient an effective quantity of 3?-methoxy-pregna-5-ene-20-one (3?-methoxy-PREG).
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: May 17, 2016
    Assignee: MAPREG
    Inventors: Etienne-Emile Baulieu, Esther Fellous, Paul Robel
  • THE USE OF 3-METHOXY-PREGNENOLONE FOR HTE PREPARATION OF A DRUG FOR TREATING A TRAUMATIC BRAIN INURY
    Publication number: 20140228336
    Abstract: A method for the treatment of a traumatic brain lesion comprises administering to the patient an effective quantity of 3?-methoxy-pregna-5-ene-20-one (3?-methoxy-PREG).
    Type: Application
    Filed: November 1, 2012
    Publication date: August 14, 2014
    Applicant: MAPREG
    Inventors: Etienne-Emile BAULIEU, Esther FELLOUS, Paul ROBEL
  • USE OF 3-METHOXY-PREGNENOLONE FOR THE PREPARATION OF A DRUG FOR TREATING DEPRESSIVE DISORDERS AND LONG-TERM NEUROLOGICAL DISEASES
    Publication number: 20130244991
    Abstract: A method for the treatment of a traumatic brain lesion comprises administering to the patient an effective quantity of 3?-methoxy-pregna-5-ene-20-one (3?-methoxy-PREG).
    Type: Application
    Filed: November 1, 2012
    Publication date: September 19, 2013
    Applicant: MAPREG
    Inventors: Etienne-Emile BAULIEU, Ester FELLOUS, Paul ROBEL, Massimiliano BIANCHI
  • Use of 3-methoxy-pregnenolone for the preparation of a drug for treating depressive disorders and long-term neurological diseases
    Patent number: 8334278
    Abstract: The invention relates to the therapeutic use of pregnenolone derivatives for treating depressive disorders and long-term neurological diseases.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: December 18, 2012
    Assignee: Mapreg
    Inventors: Etienne-Emile Baulieu, Ester Fellous, Paul Robel, Massimiliano Bianchi
  • Use of 3-methoxy-pregnenolone in the production of a medicament for treating neurodegenerative diseases
    Patent number: 8034798
    Abstract: The invention relates to a novel use of derivatives of neurosteroids, particularly pregnenolone, for the treatment of acute or chronic lesions of the nervous system, especially certain neurodegenerative diseases, related in particular to the ability thereof to stabilize and/or increase the polymerization of neuronal microtubules.
    Type: Grant
    Filed: January 16, 2004
    Date of Patent: October 11, 2011
    Assignee: MAPREG
    Inventors: Etienne-Emile Baulieu, Esther Fellous, Paul Robel